{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:27:44Z","timestamp":1788229664017,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.anndiagpath.2020.151490","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:17:40Z","timestamp":1583241460000},"page":"151490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Histological subtypes in triple negative breast cancer are associated with specific information on survival"],"prefix":"10.1016","volume":"46","author":[{"given":"Maschenka C.A.","family":"Balkenhol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Vreuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla A.P.","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J.J.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen A.W.M.","family":"van der Laak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2020.151490_bb0005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0010","series-title":"WHO classification of tumours of the breast","author":"Lakhani","year":"2012"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0015","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sj.bjc.6602787","article-title":"Clinical characteristics of different histologic types of breast cancer","volume":"93","author":"Li","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0020","series-title":"Rosen\u2019s breast pathology","author":"Hoda","year":"2014"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0025","doi-asserted-by":"crossref","unstructured":"Jacquemier J, Padovani L, Rabayrol L, et al; European Working Group for Breast Screening Pathology; Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal\/myoepithelial phenotype. J Pathol 2005;207:260\u20138.","DOI":"10.1002\/path.1845"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2559.2012.04230.x","article-title":"Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type","volume":"61","author":"Monhollen","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1245\/s10434-006-9124-7","article-title":"Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base","volume":"14","author":"Pezzi","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/bjc.2014.592","article-title":"Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study","volume":"112","author":"Rakha","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2325\/jbcs.12.189","article-title":"Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast","volume":"12","author":"Kuroda","year":"2005","journal-title":"Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0050","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0060","doi-asserted-by":"crossref","first-page":"45411","DOI":"10.1038\/srep45411","article-title":"Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0065","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41467-018-03283-z","article-title":"Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer","volume":"9","author":"Patel","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0070","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0075","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1078-0432.CCR-14-2532","article-title":"Translating the molecular message of triple-negative breast cancer into targeted therapy","volume":"21","author":"Vidula","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0080","unstructured":"Netherlands Comprehensive Cancer Registry. Guideline breast cancer. Available from: http:\/\/www.oncoline.nl. Accessed 25 May 2018."},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0085","author":"Ellis","year":"2016"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0090","series-title":"College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Version Invasive Breast 4.0.0.0","author":"Fitzgibbons","year":"2017"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0095","series-title":"International classification of diseases for oncology","author":"Fritz","year":"2000"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0100","series-title":"AJCC cancer staging manual","author":"Edge","year":"2010"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0105","unstructured":"Foundation Federation of Dutch Medical Scientific Societies (Federa). Code of conduct for medical research. 2004. https:\/\/www.federa.org\/codes-conduct. Accessed 2 May 2018."},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0110","unstructured":"Foundation Federation of Dutch Medical Scientific Societies (Federa). Human tissue and medical research: code of conduct for responsible use. 2011. https:\/\/www.federa.org\/codes-conduct. Accessed 2 May 2018."},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0125","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/annonc\/mdv106","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0130","series-title":"AJCC cancer staging manual","author":"Greene","year":"2002"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0135","series-title":"TNM classification of malignant tumors","author":"Sobin","year":"2009"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clbc.2012.09.002","article-title":"Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome","volume":"13","author":"Montagna","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7150\/jca.22280","article-title":"The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer","volume":"9","author":"Liao","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejso.2017.11.027","article-title":"Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis","volume":"44","author":"Zhao","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-017-4499-7","article-title":"Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer","volume":"167","author":"Leon-Ferre","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12885-017-3969-y","article-title":"Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients","volume":"18","author":"Urru","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0165","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ajpath.2017.03.016","article-title":"The spectrum of triple-negative breast disease: high- and low-grade lesions","volume":"187","author":"Geyer","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.06.043","article-title":"Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: results of a national multi-institutional retrospective study","volume":"84","author":"de Nonneville","year":"2017","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.anndiagpath.2020.151490_bb0175","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","article-title":"Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann\u2019s refined classification","volume":"15","author":"Echavarria","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3349\/ymj.2011.52.1.89","article-title":"Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma","volume":"52","author":"Seung Koo","year":"2011","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0185","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/PAI.0b013e3182a5a02d","article-title":"Correlation of clinicopathologic parameters and immunohistochemical features of triple-negative invasive lobular carcinoma","volume":"22","author":"Harbhajanka","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0190","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0200","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","article-title":"Which threshold for ER positivity? A retrospective study based on 9639 patients","volume":"25","author":"Yi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151490_bb0205","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.31914","article-title":"Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study","volume":"144","author":"van Maaren","year":"2019","journal-title":"Int J Cancer"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420300319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420300319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:31:29Z","timestamp":1761078689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913420300319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":41,"alternative-id":["S1092913420300319"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151490","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histological subtypes in triple negative breast cancer are associated with specific information on survival","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151490"}}